Latest Methotrexate Stories
THE WOODLANDS, Texas, Aug. 4 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc.
DALLAS, July 7 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today new preclinical data demonstrating that thiarabine shows remarkable efficacy in the prevention and treatment of rheumatoid arthritis (RA).
Researchers have found that patients dealing with the early stages of rheumatoid arthritis could benefit from a drug currently reserved for people in the advanced stages of the disease.
Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP*) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who have achieved inactive disease status, according to a new study presented today presented today at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.
- Additional data reinforce long-term efficacy of ACTEMRA across a broad range of rheumatoid arthritis patient populations - NUTLEY, N.J., June 9 /PRNewswire/ -- One-year data from the two-year Phase III LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with ACTEMRA(R) (tocilizumab), a novel interleukin-6 (IL-6) receptor inhibitor, in combination with methotrexate, experienced a...
Dermatologists emphasize treatment should be tailored to meet individual patients' needs SCHAUMBURG, Ill., June 4 /PRNewswire-USNewswire/ -- Based on an extensive review of scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with traditional systemic therapies.
- Available this week, Cimzia(R) (certolizumab pegol), the only pegylated anti-TNF, offers a new treatment option for U.S.
The U.S. Food and Drug Administration says it has approved Simponi, a monthly injectable treatment for three types of arthritis. The FDA said Simponi (golimumab) was approved for use by adults with moderate-to-severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.
Canadian Approval Is World's First Regulatory Approval for SIMPONI HORSHAM, Pa. and KENILWORTH, N.J., April 13 /PRNewswire-FirstCall/ Centocor Ortho Biotech Inc.
JAKARTA, Indonesia, April 9 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints.
- A trick or prank.